{"id":5478,"date":"2022-02-07T14:24:14","date_gmt":"2022-02-07T12:24:14","guid":{"rendered":"https:\/\/covid-19-bilgi.de\/?page_id=5478"},"modified":"2022-11-29T12:41:39","modified_gmt":"2022-11-29T10:41:39","slug":"almanyada-asilama","status":"publish","type":"page","link":"https:\/\/covid-19-bilgi.de\/tr\/almanyada-asilama\/","title":{"rendered":"A\u015f\u0131 Maddeleri"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

COVID-19'a Kar\u015f\u0131<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t

A\u015f\u0131 Maddeleri<\/h1>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

Be\u015f A\u015f\u0131 Onayland\u0131<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Be\u015f A\u015f\u0131, \u00dc\u00e7 Farkl\u0131 Y\u00f6ntem<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

mRNA A\u015f\u0131lar\u0131<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

BioNTech\/Pfizer ve Moderna a\u015f\u0131lar\u0131 mRNA a\u015f\u0131lar\u0131d\u0131r. mRNA\u00a0a\u015f\u0131lar\u0131 haberci RNA’dan (mRNA, mesajc\u0131 RNA) olu\u015fur. RNA, ribon\u00fckleik asidin k\u0131saltmas\u0131d\u0131r. RNA, genetik bilginin ta\u015f\u0131y\u0131c\u0131s\u0131d\u0131r. BioNTech\/Pfizer ve Moderna’n\u0131n a\u015f\u0131lar\u0131n\u0131n haberci RNA’s\u0131, koronavir\u00fcs SARS-CoV-2’nin y\u00fczey proteininin (ba\u015fak proteini) \u00fcretimi i\u00e7in gereken yap\u0131 plan\u0131 talimatlar\u0131n\u0131n genetik bilgilerini i\u00e7erir.<\/p>

V\u00fccuttaki h\u00fccreler, a\u015f\u0131laman\u0131n ard\u0131ndan (mRNA\u2019n\u0131n) bu yap\u0131 plan\u0131na bakarak proteinler \u00fcretmeye ba\u015flar. Bu proteinler ise ba\u011f\u0131\u015f\u0131kl\u0131k sistemini SARS-CoV-2\u2018ye kar\u015f\u0131 hedefli bir \u015fekilde antikor olu\u015fturmaya ve SARS-CoV-2 ile enfekte olmu\u015f h\u00fccrelere kar\u015f\u0131 h\u00fccresel d\u00fczeyde diren\u00e7 g\u00f6stermeye sevk ederek, b\u00f6ylece iyi bir imm\u00fcn reaksiyonu ortaya \u00e7\u0131kar\u0131r. Bu proteinlerin di\u011fer bir ad\u0131 da antikordur.<\/p>

A\u015f\u0131lanan ki\u015fi daha sonra koronavir\u00fcs ile temas ederse, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi taraf\u0131ndan tan\u0131n\u0131r ve m\u00fccadele edilir.<\/p>

Bu noktada bilinmesinde fayda olan \u015fu noktaya da dikkat \u00e7ekelim: Mesajc\u0131 RNA, k\u0131sa s\u00fcre i\u00e7erisinde tekrar v\u00fccuttan at\u0131l\u0131r. \u0130nsan DNA\u2019s\u0131na d\u00f6n\u00fc\u015fmez ve insan geni \u00fczerinde etkisi de yoktur. mRNA v\u00fccuttan at\u0131ld\u0131ktan sonra antijen \u00fcretimi devam etmez.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\tViral Vekt\u00f6r A\u015f\u0131lar\u0131\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

AstraZeneca ve Johnson & Johnson a\u015f\u0131lar\u0131 vekt\u00f6r a\u015f\u0131lard\u0131r. A\u015f\u0131, vekt\u00f6r vir\u00fcsleri ad\u0131 verilen yap\u0131lar\u0131 i\u00e7erirler. Bu vir\u00fcsler, vekt\u00f6r vir\u00fcs ad\u0131 verilen ve bug\u00fcne dek \u00fczerinde ayr\u0131nt\u0131l\u0131 ara\u015ft\u0131rmalar yap\u0131lm\u0131\u015f olan bir vir\u00fcst\u00fcr ve bu vir\u00fcs\u00fcn a\u015f\u0131lanan ki\u015finin v\u00fccudunda \u00e7o\u011falmas\u0131 m\u00fcmk\u00fcn de\u011fildir. Bu a\u015f\u0131larda, korona vir\u00fcsteki tek bir proteinin \u2013 yani spike proteinin – genetik bilgisini i\u00e7eren bir adenovir\u00fcst\u00fcr (so\u011fuk alg\u0131nl\u0131\u011f\u0131 vir\u00fcs\u00fc).<\/p><\/div>

Vekt\u00f6r vir\u00fcs\u00fcn i\u015flevi, bu bilgilerin v\u00fccuda ta\u015f\u0131narak h\u00fccrelerin bu bilgileri \u201cokumas\u0131\u201d ve buna ba\u011fl\u0131 olarak spike proteini kendilerinin \u00fcretmesidir. Bu \u015fekilde v\u00fccut taraf\u0131ndan \u00fcretilen spike proteinler ba\u011f\u0131\u015f\u0131kl\u0131k sistemi taraf\u0131ndan yabanc\u0131 protein olarak de\u011ferlendirilir. Ba\u011f\u0131\u015f\u0131kl\u0131k sistemi de bunun \u00fczerine koronavir\u00fcse kar\u015f\u0131 savunma h\u00fccreleri olu\u015fturur. Bu \u015fekilde koruyucu bir ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131 ortaya \u00e7\u0131kar.<\/p><\/div>

Bilmekte fayda var: Spike protein tek ba\u015f\u0131na SARS-CoV-2 enfeksiyonuna yol a\u00e7amaz. Ayn\u0131 \u015fekilde v\u00fccut k\u0131sa s\u00fcrede vekt\u00f6r vir\u00fcs\u00fc atar ve buna ba\u011fl\u0131 olarak vir\u00fcs proteininin (spike protein) \u00fcretimi devam etmez.<\/p>

A\u015f\u0131lanan ki\u015fi daha sonra koronavir\u00fcs ile temas ederse, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi taraf\u0131ndan tan\u0131n\u0131r ve m\u00fccadele edilir. Vekt\u00f6r a\u015f\u0131lar\u0131 zaten denenmi\u015f ve test edilmi\u015ftir ve \u00f6rne\u011fin Ebola’ya kar\u015f\u0131 koruma sa\u011flamak i\u00e7in kullan\u0131lmaktad\u0131r.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

\u0130naktif A\u015f\u0131lar<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

20 Aral\u0131k 2021’de Avrupa \u0130la\u00e7 Ajans\u0131 (EMA), ABD ila\u00e7 \u015firketi Novavax’tan ilk protein bazl\u0131 COVID-19 a\u015f\u0131s\u0131 Nuvaxovid’in onaylanmas\u0131n\u0131 \u00f6nerdi. Bu, art\u0131k\u00a0Almanya’da da COVID-19’a kar\u015f\u0131 koruma sa\u011flayacak bir rekombinant protein a\u015f\u0131s\u0131n\u0131n, daha geni\u015f anlamda inaktif bir a\u015f\u0131n\u0131n\u00a0mevcut oldu\u011fu anlam\u0131na geliyor.<\/p>

Di\u011fer COVID-19 a\u015f\u0131lar\u0131 gibi Novavax’\u0131n Nuvaxovid\u00ae a\u015f\u0131s\u0131 da v\u00fccudu koronavir\u00fcs enfeksiyonuyla sava\u015fmaya haz\u0131rlamak i\u00e7in tasarlanm\u0131\u015ft\u0131r. A\u015f\u0131, laboratuvarda \u00fcretilen ve spike proteinler olarak adland\u0131r\u0131lan k\u00fc\u00e7\u00fck koronavir\u00fcs par\u00e7ac\u0131klar\u0131n\u0131 i\u00e7ermektedir. Bu par\u00e7ac\u0131klar a\u015f\u0131 yoluyla v\u00fccuda girdi\u011finde, yabanc\u0131 olarak tan\u0131n\u0131rlar ve ba\u011f\u0131\u015f\u0131kl\u0131k sistemini antikor olu\u015fturmas\u0131 i\u00e7in uyar\u0131rlar. Bu koruyucu bir ba\u011f\u0131\u015f\u0131kl\u0131k tepkisi olu\u015fturur. V\u00fccudu spike proteinin kendisinin zarars\u0131z kopyalar\u0131n\u0131 yapmas\u0131 i\u00e7in uyaran mRNA ve vekt\u00f6r a\u015f\u0131lar\u0131n\u0131n aksine, Nuvaxovid\u00ae viral protein zarf\u0131n\u0131n h\u00fccre k\u00fclt\u00fcrl\u00fc bile\u015fenleriyle do\u011frudan a\u015f\u0131lan\u0131r. Ba\u011f\u0131\u015f\u0131kl\u0131k reaksiyonunu g\u00fc\u00e7lendirmek i\u00e7in protein a\u015f\u0131s\u0131 ayr\u0131ca bir adjuvan (g\u00fc\u00e7lendirici madde) i\u00e7erir.<\/p><\/div>

Bilmekte fayda var: Novavax’tan Nuvaxovid\u00ae gibi protein bazl\u0131 a\u015f\u0131lar, kendilerini \u00e7o\u011faltabilen veya hastal\u0131\u011fa neden olabilecek herhangi bir patojen veya patojen bile\u015feni i\u00e7ermez. Bir\u00e7ok grip a\u015f\u0131s\u0131 da bu prensibe g\u00f6re \u00e7al\u0131\u015f\u0131r – burada influenza vir\u00fcslerinden gelen protein par\u00e7ac\u0131klar\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k reaksiyonunu tetikler.<\/p><\/div>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

G\u00fcncellik: 02.2022,<\/em> Kaynak: Bundesministerium f\u00fcr Gesundheit<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

A\u015f\u0131lar\u0131n \u00d6zellik ve Etkinlikleri*<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t
<\/figcaption>\n\t\t\t\t\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

\u00a9 Federal Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131, G\u00fcncellik: Haziran 2022, Kaynaklar: Avrupa onay\u0131, Daimi A\u015f\u0131 Komisyonunun (STIKO) tavsiyeleri, Federal Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131n\u0131n A\u015f\u0131 Y\u00f6netmeli\u011fi. * Rakamlar, ilk tamamlanm\u0131\u015f a\u015f\u0131 serisinden sonraki verileri g\u00f6stermektedir. T\u00fcm a\u015f\u0131lar\u0131n etkinli\u011fi hafif hastal\u0131k seyrine kar\u015f\u0131 daha d\u00fc\u015f\u00fckt\u00fcr. **Veriler, Johnson & Johnson’dan Janssen\u00ae a\u015f\u0131s\u0131 ile tek bir a\u015f\u0131 dozuna ili\u015fkindir. A\u015f\u0131n\u0131n Delta varyant\u0131na kar\u015f\u0131 daha d\u00fc\u015f\u00fck koruyucu etkisinden dolay\u0131 STIKO, mRNA a\u015f\u0131s\u0131 ile ikinci bir doz a\u015f\u0131 yap\u0131lmas\u0131n\u0131 \u00f6nerilir.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

A\u015f\u0131da Ya\u015fanabilecek\u00a0Tipik Reaksiyonlar<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

A\u015f\u0131lama sonras\u0131 semptomlar ciddi yan etkilerin de\u011fil, ba\u011f\u0131\u015f\u0131kl\u0131k\u00a0sisteminin \u00e7al\u0131\u015fmaya ba\u015flad\u0131\u011f\u0131n\u0131n bir i\u015faretidir. Bu nedenle,\u00a0sonu\u00e7ta korkun\u00e7 hastal\u0131\u011fa kar\u015f\u0131 korumaya yol a\u00e7an etkinin bir\u00a0par\u00e7as\u0131d\u0131rlar.\u00a0A\u015f\u0131lama reaksiyonlar\u0131 genellikle a\u015f\u0131lamadan k\u0131sa bir s\u00fcre sonra ortaya \u00e7\u0131kar ve birka\u00e7 g\u00fcn s\u00fcrer.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

mRNA A\u015f\u0131lar\u0131<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

mRNA as\u0327\u0131lar\u0131ndan birini olduktan sonra a\u015f\u0131n\u0131n v\u00fccutla etkile\u015fime ge\u00e7mesi sonucunda lokal ve genel baz\u0131 reaksiyonlar g\u00f6r\u00fclebilir.<\/p>

Veri taban\u0131: mRNA a\u015f\u0131lar\u0131
(BioNTech\/Pfizer\u00a0a\u015f\u0131lar\u0131n yuvarlat\u0131lm\u0131\u015f yu\u0308zdesi)<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\tA\u015f\u0131 uygulanan b\u00f6lgede a\u011fr\u0131<\/span>\n\t\t\n\t\t
\n\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t80%<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\tYorgunluk<\/span>\n\t\t\n\t\t
\n\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t60%<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\tBa\u015f a\u011fr\u0131s\u0131<\/span>\n\t\t\n\t\t
\n\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t50%<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\tKas a\u011fr\u0131s\u0131<\/span>\n\t\t\n\t\t
\n\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t30%<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\tTitreme<\/span>\n\t\t\n\t\t
\n\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t30%<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\tEklem a\u011fr\u0131s\u0131<\/span>\n\t\t\n\t\t
\n\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t20%<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\tve ayr\u0131ca y\u00fczde 10’dan fazla\u00a0ates\u0327 ve enjeksiyon bo\u0308lgesinde s\u0327is\u0327me g\u00f6r\u00fclm\u00fc\u015ft\u00fcr. S\u0131kl\u0131kla (%1ile %10 aras\u0131nda) bulant\u0131 ve enjeksiyon bo\u0308lgesinde k\u0131zar\u0131kl\u0131k meydana gelmis\u0327tir. Nadiren (%0,1 ile %1 aras\u0131nda), enjeksiyon bo\u0308lgesinde lenf du\u0308g\u0306u\u0308mlerinde s\u0327is\u0327lik, uykusuzluk, kol veya bacakta ag\u0306r\u0131, rahats\u0131zl\u0131k ve kas\u0327\u0131nt\u0131 go\u0308ru\u0308lmu\u0308s\u0327tu\u0308r.\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\tKaynak:\u00a0RKI kay\u0131t verileri\u00a0| G\u00fcncellik: Mart 2021\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

Vekt\u00f6r A\u015f\u0131lar\u0131<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Vekt\u00f6r as\u0327\u0131lar\u0131ndan birini olduktan sonra a\u015f\u0131n\u0131n v\u00fccutla etkile\u015fime ge\u00e7mesi sonucunda lokal ve genel reaksiyonlar g\u00f6r\u00fclebilir.<\/p>

Veri taban\u0131: Vekt\u00f6r a\u015f\u0131lar\u0131
(COVID-19 Vaccine Janssen\u00ae a\u015f\u0131s\u0131n\u0131n yuvarlat\u0131lm\u0131\u015f yu\u0308zdesi)<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\tA\u015f\u0131 uygulanan b\u00f6lgede a\u011fr\u0131<\/span>\n\t\t\n\t\t
\n\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t40%<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\tBa\u015f a\u011fr\u0131s\u0131<\/span>\n\t\t\n\t\t
\n\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t30%<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\tYorgunluk<\/span>\n\t\t\n\t\t
\n\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t30%<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\tKas a\u011fr\u0131s\u0131<\/span>\n\t\t\n\t\t
\n\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t30%<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\tBulant\u0131<\/span>\n\t\t\n\t\t
\n\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t10%<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\tve ayr\u0131ca s\u0131kl\u0131kla (% 1 ile% 10 aras\u0131nda) ate\u015f,\u00f6ks\u00fcr\u00fck, eklem a\u011fr\u0131s\u0131, enjeksiyon b\u00f6lgesinde k\u0131zar\u0131kl\u0131k ve \u015fi\u015flik ve titreme yayg\u0131n olarak bildirilmi\u015ftir. Nadiren (% 0,1 ile% 1 aras\u0131nda) titreme, hap\u015f\u0131rma, a\u011f\u0131z ve bo\u011fazda a\u011fr\u0131, genel d\u00f6k\u00fcnt\u00fc, terlemede art\u0131\u015f, kas g\u00fc\u00e7s\u00fczl\u00fc\u011f\u00fc, kol veya bacak a\u011fr\u0131s\u0131, s\u0131rt a\u011fr\u0131s\u0131, genel halsizlik ve halsizlik g\u00f6r\u00fclm\u00fc\u015ft\u00fcr.\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\tKaynak:\u00a0RKI kay\u0131t verileri\u00a0| G\u00fcncellik: Nisan 2021\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

\u0130naktif A\u015f\u0131lar<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Protein bazl\u0131 olan bir as\u0327\u0131 olduktan sonra a\u015f\u0131n\u0131n v\u00fccutla etkile\u015fime ge\u00e7mesi sonucunda lokal ve genel reaksiyonlar g\u00f6r\u00fclebilir.<\/p>

Veri taban\u0131: Protein bazl\u0131 a\u015f\u0131lar
(Nuvaxovid\u00ae a\u015f\u0131s\u0131n\u0131n yuvarlat\u0131lm\u0131\u015f yu\u0308zdesi)<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\tEnjeksiyon b\u00f6lgesinde hassasiyet<\/span>\n\t\t\n\t\t
\n\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t75%<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\tA\u015f\u0131 uygulanan b\u00f6lgede a\u011fr\u0131<\/span>\n\t\t\n\t\t
\n\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t62%<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\u015eiddetli yorgunluk<\/span>\n\t\t\n\t\t
\n\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t53%<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\tKas a\u011fr\u0131s\u0131<\/span>\n\t\t\n\t\t
\n\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t51%<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\tBa\u015f a\u011fr\u0131s\u0131 <\/span>\n\t\t\n\t\t
\n\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t50%<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\tGenel halsizlik<\/span>\n\t\t\n\t\t
\n\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t41%<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\tve ayr\u0131ca y\u00fczde 24 eklem a\u011fr\u0131s\u0131 ve y\u00fczde 15 bulant\u0131 veya kusma g\u00f6r\u00fclm\u00fc\u015ft\u00fcr. S\u0131kl\u0131kla (% 1 ile% 10 aras\u0131nda) enjeksiyon yerinde k\u0131zar\u0131kl\u0131k veya \u015fi\u015flik, ate\u015f, titreme ve kol, el, bacak ve\/veya ayakta a\u011fr\u0131 bildirilmi\u015ftir. Nadiren (% 0,1 ile% 1 aras\u0131nda) lenf d\u00fc\u011f\u00fcmlerinde \u015fi\u015fme, y\u00fcksek tansiyon, enjeksiyon b\u00f6lgesinde ka\u015f\u0131nt\u0131l\u0131 cilt veya ka\u015f\u0131nt\u0131, d\u00f6k\u00fcnt\u00fc, kurde\u015fen veya ciltte k\u0131zar\u0131kl\u0131k g\u00f6r\u00fclm\u00fc\u015ft\u00fcr.\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\tKaynak: RKI kay\u0131t verileri | G\u00fcncellik: \u015eubat 2022\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

COVID-19’a Kar\u015f\u0131 A\u015f\u0131 Maddeleri Be\u015f A\u015f\u0131 Onayland\u0131 Be\u015f A\u015f\u0131, \u00dc\u00e7 Farkl\u0131 Y\u00f6ntem mRNA A\u015f\u0131lar\u0131 BioNTech\/Pfizer ve Moderna a\u015f\u0131lar\u0131 mRNA a\u015f\u0131lar\u0131d\u0131r. mRNA\u00a0a\u015f\u0131lar\u0131 haberci RNA’dan (mRNA, mesajc\u0131 RNA) olu\u015fur. RNA, ribon\u00fckleik asidin k\u0131saltmas\u0131d\u0131r. RNA, genetik bilginin ta\u015f\u0131y\u0131c\u0131s\u0131d\u0131r. BioNTech\/Pfizer ve Moderna’n\u0131n a\u015f\u0131lar\u0131n\u0131n haberci RNA’s\u0131, koronavir\u00fcs SARS-CoV-2’nin y\u00fczey proteininin (ba\u015fak proteini) \u00fcretimi i\u00e7in gereken yap\u0131 plan\u0131 talimatlar\u0131n\u0131n genetik bilgilerini […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/pages\/5478"}],"collection":[{"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/comments?post=5478"}],"version-history":[{"count":105,"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/pages\/5478\/revisions"}],"predecessor-version":[{"id":8362,"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/pages\/5478\/revisions\/8362"}],"wp:attachment":[{"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/media?parent=5478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}